Compare Brown-Forman Corporation Class B (BF.B) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brown-Forman Corporation Class B vs Boston Scientific Corporation — how do they compare? Brown-Forman Corporation Class B trades at $25.18, while Boston Scientific Corporation trades at $42.51 (market cap $66.37B). The key difference: Brown-Forman Corporation Class B is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BF.B | BSX | |
|---|---|---|
Sector | Consumer Staples | Health |
52-Week High | $31.26 | $108.14 |
52-Week Low | $22.80 | $42.63 |
Market Cap | — | $66.37B |
Enterprise Value | — | $75.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BF.B trades at $26.25, up 0.31% on the day, with a bearish technical signal from moving averages but mixed oscillators. Recent earnings show three consecutive beats, with Q2 2024 EPS of $0.48 exceeding the $0.46 estimate. Analyst sentiment is divided, with a 25% buy rating amid cautious technical indicators.
The stock's outlook is balanced by strong earnings momentum against bearish technicals. Opportunities lie in continued earnings outperformance, while risks include weak technical trends and lack of consensus among analysts. Investors should weigh fundamental strength against near-term price pressure.
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
